Global Ambrisentan Drug Market
Global Ambrisentan Drug Market

Ambrisentan Drug Comprehensive Study by Impairment Type (Renal Impairment, Hepatic Impairment), End-Use (Hospitals, Specialty Drug Store), Strength (5mg, 10mg) Players and Region - Global Market Outlook to 2026

Ambrisentan Drug Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Mar 2021 Edition 217 Pages 216 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Ambrisentan Drug Market?

Ambrisentan is basically an orally active type A selective endothelin receptor antagonist that is hereby indicated for the treatment of pulmonary arterial hypertension. It has been approved in Europe, Canada, and the United States for being used as a single agent for improving exercise ability as well as delay clinical deterioration. In addition to all these, it has also been approved in the US for being used in the combination with tadalafil so as to reduce the risk of hospitalization, disease progression, and improvement in exercising capacity. Ambrisentan consumption can further lead to a high risk of liver damage and can also cause birth defects if a woman becomes pregnant while taking it. In the United States, prescribers and patients taking it must enroll in a special program called the LETAIRIS Education and Access Program (LEAP) so as to learn more about the risks associated with the consumption of the drug. Ambrisentan is only available in specialty pharmacies.

The market study is being classified and major geographies with country level break-up.

Mylan S.A.S. (United States), Gilead Sciences, Inc. (United States), Glaxo Smith Kline Limited (United Kingdom), Cipla Inc. (India), Par Pharmaceutical, Inc. (United States), Sigmapharm Laboratories, LLC (United States), Sun Pharmaceutical Industries, Inc. (India), Cadila Healthcare Limited (India), Exelan Pharmaceuticals, Inc. (United States), Actavis Pharma, Inc. (United States) and Hansoh Pharma (China) are some of the key players profiled in the study.

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Ambrisentan Drug market throughout the predicted period.

Segment Analysis
Analyst at AMA have segmented the market study of Global Ambrisentan Drug market by Type, Application and Region.

On the basis of geography, the market of Ambrisentan Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Drivers
  • Rapid Urbanization and Globalization, Human Health Is Being Adversely Affected
  • Change In Lifestyle and Elevated Stress Levels

Market Trend
  • Rising Awareness about Mental Health
  • Huge Funding In R&D and Various Initiatives by Government

Restraints
  • Relative Side Effects by the Use of Ambrisentan Drugs

Opportunities
  • Growing Improvements and Developments across the Healthcare Industry
  • Improved Awareness among People Regarding Hypertension and Its Available Treatment Options

Challenges
  • Availability of Alternative Therapies





Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Manufacturers of Ambrisentan Drug, Suppliers and Distributors of Ambrisentan Drug, Venture Capitalists and Private Equity Firms and End-Use Industry

Customization in the Report Available:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Impairment Type
  • Renal Impairment
  • Hepatic Impairment

By End-Use
  • Hospitals
  • Specialty Drug Store

By Strength
  • 5mg
  • 10mg

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rapid Urbanization and Globalization, Human Health Is Being Adversely Affected
      • 3.2.2. Change In Lifestyle and Elevated Stress Levels
    • 3.3. Market Challenges
      • 3.3.1. Availability of Alternative Therapies
    • 3.4. Market Trends
      • 3.4.1. Rising Awareness about Mental Health
      • 3.4.2. Huge Funding In R&D and Various Initiatives by Government
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Ambrisentan Drug, by Impairment Type, End-Use, Strength and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Ambrisentan Drug (Value)
      • 5.2.1. Global Ambrisentan Drug by: Impairment Type (Value)
        • 5.2.1.1. Renal Impairment
        • 5.2.1.2. Hepatic Impairment
      • 5.2.2. Global Ambrisentan Drug by: End-Use (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Specialty Drug Store
      • 5.2.3. Global Ambrisentan Drug by: Strength (Value)
        • 5.2.3.1. 5mg
        • 5.2.3.2. 10mg
      • 5.2.4. Global Ambrisentan Drug Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Ambrisentan Drug (Volume)
      • 5.3.1. Global Ambrisentan Drug by: Impairment Type (Volume)
        • 5.3.1.1. Renal Impairment
        • 5.3.1.2. Hepatic Impairment
      • 5.3.2. Global Ambrisentan Drug by: End-Use (Volume)
        • 5.3.2.1. Hospitals
        • 5.3.2.2. Specialty Drug Store
      • 5.3.3. Global Ambrisentan Drug by: Strength (Volume)
        • 5.3.3.1. 5mg
        • 5.3.3.2. 10mg
      • 5.3.4. Global Ambrisentan Drug Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Ambrisentan Drug (Price)
  • 6. Ambrisentan Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Mylan S.A.S. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Gilead Sciences, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Glaxo Smith Kline Limited (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Cipla Inc. (India)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Par Pharmaceutical, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Sigmapharm Laboratories, LLC (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Sun Pharmaceutical Industries, Inc. (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Cadila Healthcare Limited (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Exelan Pharmaceuticals, Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Actavis Pharma, Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Hansoh Pharma (China)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Ambrisentan Drug Sale, by Impairment Type, End-Use, Strength and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Ambrisentan Drug (Value)
      • 7.2.1. Global Ambrisentan Drug by: Impairment Type (Value)
        • 7.2.1.1. Renal Impairment
        • 7.2.1.2. Hepatic Impairment
      • 7.2.2. Global Ambrisentan Drug by: End-Use (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Specialty Drug Store
      • 7.2.3. Global Ambrisentan Drug by: Strength (Value)
        • 7.2.3.1. 5mg
        • 7.2.3.2. 10mg
      • 7.2.4. Global Ambrisentan Drug Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Ambrisentan Drug (Volume)
      • 7.3.1. Global Ambrisentan Drug by: Impairment Type (Volume)
        • 7.3.1.1. Renal Impairment
        • 7.3.1.2. Hepatic Impairment
      • 7.3.2. Global Ambrisentan Drug by: End-Use (Volume)
        • 7.3.2.1. Hospitals
        • 7.3.2.2. Specialty Drug Store
      • 7.3.3. Global Ambrisentan Drug by: Strength (Volume)
        • 7.3.3.1. 5mg
        • 7.3.3.2. 10mg
      • 7.3.4. Global Ambrisentan Drug Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Ambrisentan Drug (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Ambrisentan Drug: by Impairment Type(USD Million)
  • Table 2. Ambrisentan Drug Renal Impairment , by Region USD Million (2015-2020)
  • Table 3. Ambrisentan Drug Hepatic Impairment , by Region USD Million (2015-2020)
  • Table 4. Ambrisentan Drug: by End-Use(USD Million)
  • Table 5. Ambrisentan Drug Hospitals , by Region USD Million (2015-2020)
  • Table 6. Ambrisentan Drug Specialty Drug Store , by Region USD Million (2015-2020)
  • Table 7. Ambrisentan Drug: by Strength(USD Million)
  • Table 8. Ambrisentan Drug 5mg , by Region USD Million (2015-2020)
  • Table 9. Ambrisentan Drug 10mg , by Region USD Million (2015-2020)
  • Table 10. South America Ambrisentan Drug, by Country USD Million (2015-2020)
  • Table 11. South America Ambrisentan Drug, by Impairment Type USD Million (2015-2020)
  • Table 12. South America Ambrisentan Drug, by End-Use USD Million (2015-2020)
  • Table 13. South America Ambrisentan Drug, by Strength USD Million (2015-2020)
  • Table 14. Brazil Ambrisentan Drug, by Impairment Type USD Million (2015-2020)
  • Table 15. Brazil Ambrisentan Drug, by End-Use USD Million (2015-2020)
  • Table 16. Brazil Ambrisentan Drug, by Strength USD Million (2015-2020)
  • Table 17. Argentina Ambrisentan Drug, by Impairment Type USD Million (2015-2020)
  • Table 18. Argentina Ambrisentan Drug, by End-Use USD Million (2015-2020)
  • Table 19. Argentina Ambrisentan Drug, by Strength USD Million (2015-2020)
  • Table 20. Rest of South America Ambrisentan Drug, by Impairment Type USD Million (2015-2020)
  • Table 21. Rest of South America Ambrisentan Drug, by End-Use USD Million (2015-2020)
  • Table 22. Rest of South America Ambrisentan Drug, by Strength USD Million (2015-2020)
  • Table 23. Asia Pacific Ambrisentan Drug, by Country USD Million (2015-2020)
  • Table 24. Asia Pacific Ambrisentan Drug, by Impairment Type USD Million (2015-2020)
  • Table 25. Asia Pacific Ambrisentan Drug, by End-Use USD Million (2015-2020)
  • Table 26. Asia Pacific Ambrisentan Drug, by Strength USD Million (2015-2020)
  • Table 27. China Ambrisentan Drug, by Impairment Type USD Million (2015-2020)
  • Table 28. China Ambrisentan Drug, by End-Use USD Million (2015-2020)
  • Table 29. China Ambrisentan Drug, by Strength USD Million (2015-2020)
  • Table 30. Japan Ambrisentan Drug, by Impairment Type USD Million (2015-2020)
  • Table 31. Japan Ambrisentan Drug, by End-Use USD Million (2015-2020)
  • Table 32. Japan Ambrisentan Drug, by Strength USD Million (2015-2020)
  • Table 33. India Ambrisentan Drug, by Impairment Type USD Million (2015-2020)
  • Table 34. India Ambrisentan Drug, by End-Use USD Million (2015-2020)
  • Table 35. India Ambrisentan Drug, by Strength USD Million (2015-2020)
  • Table 36. South Korea Ambrisentan Drug, by Impairment Type USD Million (2015-2020)
  • Table 37. South Korea Ambrisentan Drug, by End-Use USD Million (2015-2020)
  • Table 38. South Korea Ambrisentan Drug, by Strength USD Million (2015-2020)
  • Table 39. Taiwan Ambrisentan Drug, by Impairment Type USD Million (2015-2020)
  • Table 40. Taiwan Ambrisentan Drug, by End-Use USD Million (2015-2020)
  • Table 41. Taiwan Ambrisentan Drug, by Strength USD Million (2015-2020)
  • Table 42. Australia Ambrisentan Drug, by Impairment Type USD Million (2015-2020)
  • Table 43. Australia Ambrisentan Drug, by End-Use USD Million (2015-2020)
  • Table 44. Australia Ambrisentan Drug, by Strength USD Million (2015-2020)
  • Table 45. Rest of Asia-Pacific Ambrisentan Drug, by Impairment Type USD Million (2015-2020)
  • Table 46. Rest of Asia-Pacific Ambrisentan Drug, by End-Use USD Million (2015-2020)
  • Table 47. Rest of Asia-Pacific Ambrisentan Drug, by Strength USD Million (2015-2020)
  • Table 48. Europe Ambrisentan Drug, by Country USD Million (2015-2020)
  • Table 49. Europe Ambrisentan Drug, by Impairment Type USD Million (2015-2020)
  • Table 50. Europe Ambrisentan Drug, by End-Use USD Million (2015-2020)
  • Table 51. Europe Ambrisentan Drug, by Strength USD Million (2015-2020)
  • Table 52. Germany Ambrisentan Drug, by Impairment Type USD Million (2015-2020)
  • Table 53. Germany Ambrisentan Drug, by End-Use USD Million (2015-2020)
  • Table 54. Germany Ambrisentan Drug, by Strength USD Million (2015-2020)
  • Table 55. France Ambrisentan Drug, by Impairment Type USD Million (2015-2020)
  • Table 56. France Ambrisentan Drug, by End-Use USD Million (2015-2020)
  • Table 57. France Ambrisentan Drug, by Strength USD Million (2015-2020)
  • Table 58. Italy Ambrisentan Drug, by Impairment Type USD Million (2015-2020)
  • Table 59. Italy Ambrisentan Drug, by End-Use USD Million (2015-2020)
  • Table 60. Italy Ambrisentan Drug, by Strength USD Million (2015-2020)
  • Table 61. United Kingdom Ambrisentan Drug, by Impairment Type USD Million (2015-2020)
  • Table 62. United Kingdom Ambrisentan Drug, by End-Use USD Million (2015-2020)
  • Table 63. United Kingdom Ambrisentan Drug, by Strength USD Million (2015-2020)
  • Table 64. Netherlands Ambrisentan Drug, by Impairment Type USD Million (2015-2020)
  • Table 65. Netherlands Ambrisentan Drug, by End-Use USD Million (2015-2020)
  • Table 66. Netherlands Ambrisentan Drug, by Strength USD Million (2015-2020)
  • Table 67. Rest of Europe Ambrisentan Drug, by Impairment Type USD Million (2015-2020)
  • Table 68. Rest of Europe Ambrisentan Drug, by End-Use USD Million (2015-2020)
  • Table 69. Rest of Europe Ambrisentan Drug, by Strength USD Million (2015-2020)
  • Table 70. MEA Ambrisentan Drug, by Country USD Million (2015-2020)
  • Table 71. MEA Ambrisentan Drug, by Impairment Type USD Million (2015-2020)
  • Table 72. MEA Ambrisentan Drug, by End-Use USD Million (2015-2020)
  • Table 73. MEA Ambrisentan Drug, by Strength USD Million (2015-2020)
  • Table 74. Middle East Ambrisentan Drug, by Impairment Type USD Million (2015-2020)
  • Table 75. Middle East Ambrisentan Drug, by End-Use USD Million (2015-2020)
  • Table 76. Middle East Ambrisentan Drug, by Strength USD Million (2015-2020)
  • Table 77. Africa Ambrisentan Drug, by Impairment Type USD Million (2015-2020)
  • Table 78. Africa Ambrisentan Drug, by End-Use USD Million (2015-2020)
  • Table 79. Africa Ambrisentan Drug, by Strength USD Million (2015-2020)
  • Table 80. North America Ambrisentan Drug, by Country USD Million (2015-2020)
  • Table 81. North America Ambrisentan Drug, by Impairment Type USD Million (2015-2020)
  • Table 82. North America Ambrisentan Drug, by End-Use USD Million (2015-2020)
  • Table 83. North America Ambrisentan Drug, by Strength USD Million (2015-2020)
  • Table 84. United States Ambrisentan Drug, by Impairment Type USD Million (2015-2020)
  • Table 85. United States Ambrisentan Drug, by End-Use USD Million (2015-2020)
  • Table 86. United States Ambrisentan Drug, by Strength USD Million (2015-2020)
  • Table 87. Canada Ambrisentan Drug, by Impairment Type USD Million (2015-2020)
  • Table 88. Canada Ambrisentan Drug, by End-Use USD Million (2015-2020)
  • Table 89. Canada Ambrisentan Drug, by Strength USD Million (2015-2020)
  • Table 90. Mexico Ambrisentan Drug, by Impairment Type USD Million (2015-2020)
  • Table 91. Mexico Ambrisentan Drug, by End-Use USD Million (2015-2020)
  • Table 92. Mexico Ambrisentan Drug, by Strength USD Million (2015-2020)
  • Table 93. Ambrisentan Drug Sales: by Impairment Type(K Tons)
  • Table 94. Ambrisentan Drug Sales Renal Impairment , by Region K Tons (2015-2020)
  • Table 95. Ambrisentan Drug Sales Hepatic Impairment , by Region K Tons (2015-2020)
  • Table 96. Ambrisentan Drug Sales: by End-Use(K Tons)
  • Table 97. Ambrisentan Drug Sales Hospitals , by Region K Tons (2015-2020)
  • Table 98. Ambrisentan Drug Sales Specialty Drug Store , by Region K Tons (2015-2020)
  • Table 99. Ambrisentan Drug Sales: by Strength(K Tons)
  • Table 100. Ambrisentan Drug Sales 5mg , by Region K Tons (2015-2020)
  • Table 101. Ambrisentan Drug Sales 10mg , by Region K Tons (2015-2020)
  • Table 102. South America Ambrisentan Drug Sales, by Country K Tons (2015-2020)
  • Table 103. South America Ambrisentan Drug Sales, by Impairment Type K Tons (2015-2020)
  • Table 104. South America Ambrisentan Drug Sales, by End-Use K Tons (2015-2020)
  • Table 105. South America Ambrisentan Drug Sales, by Strength K Tons (2015-2020)
  • Table 106. Brazil Ambrisentan Drug Sales, by Impairment Type K Tons (2015-2020)
  • Table 107. Brazil Ambrisentan Drug Sales, by End-Use K Tons (2015-2020)
  • Table 108. Brazil Ambrisentan Drug Sales, by Strength K Tons (2015-2020)
  • Table 109. Argentina Ambrisentan Drug Sales, by Impairment Type K Tons (2015-2020)
  • Table 110. Argentina Ambrisentan Drug Sales, by End-Use K Tons (2015-2020)
  • Table 111. Argentina Ambrisentan Drug Sales, by Strength K Tons (2015-2020)
  • Table 112. Rest of South America Ambrisentan Drug Sales, by Impairment Type K Tons (2015-2020)
  • Table 113. Rest of South America Ambrisentan Drug Sales, by End-Use K Tons (2015-2020)
  • Table 114. Rest of South America Ambrisentan Drug Sales, by Strength K Tons (2015-2020)
  • Table 115. Asia Pacific Ambrisentan Drug Sales, by Country K Tons (2015-2020)
  • Table 116. Asia Pacific Ambrisentan Drug Sales, by Impairment Type K Tons (2015-2020)
  • Table 117. Asia Pacific Ambrisentan Drug Sales, by End-Use K Tons (2015-2020)
  • Table 118. Asia Pacific Ambrisentan Drug Sales, by Strength K Tons (2015-2020)
  • Table 119. China Ambrisentan Drug Sales, by Impairment Type K Tons (2015-2020)
  • Table 120. China Ambrisentan Drug Sales, by End-Use K Tons (2015-2020)
  • Table 121. China Ambrisentan Drug Sales, by Strength K Tons (2015-2020)
  • Table 122. Japan Ambrisentan Drug Sales, by Impairment Type K Tons (2015-2020)
  • Table 123. Japan Ambrisentan Drug Sales, by End-Use K Tons (2015-2020)
  • Table 124. Japan Ambrisentan Drug Sales, by Strength K Tons (2015-2020)
  • Table 125. India Ambrisentan Drug Sales, by Impairment Type K Tons (2015-2020)
  • Table 126. India Ambrisentan Drug Sales, by End-Use K Tons (2015-2020)
  • Table 127. India Ambrisentan Drug Sales, by Strength K Tons (2015-2020)
  • Table 128. South Korea Ambrisentan Drug Sales, by Impairment Type K Tons (2015-2020)
  • Table 129. South Korea Ambrisentan Drug Sales, by End-Use K Tons (2015-2020)
  • Table 130. South Korea Ambrisentan Drug Sales, by Strength K Tons (2015-2020)
  • Table 131. Taiwan Ambrisentan Drug Sales, by Impairment Type K Tons (2015-2020)
  • Table 132. Taiwan Ambrisentan Drug Sales, by End-Use K Tons (2015-2020)
  • Table 133. Taiwan Ambrisentan Drug Sales, by Strength K Tons (2015-2020)
  • Table 134. Australia Ambrisentan Drug Sales, by Impairment Type K Tons (2015-2020)
  • Table 135. Australia Ambrisentan Drug Sales, by End-Use K Tons (2015-2020)
  • Table 136. Australia Ambrisentan Drug Sales, by Strength K Tons (2015-2020)
  • Table 137. Rest of Asia-Pacific Ambrisentan Drug Sales, by Impairment Type K Tons (2015-2020)
  • Table 138. Rest of Asia-Pacific Ambrisentan Drug Sales, by End-Use K Tons (2015-2020)
  • Table 139. Rest of Asia-Pacific Ambrisentan Drug Sales, by Strength K Tons (2015-2020)
  • Table 140. Europe Ambrisentan Drug Sales, by Country K Tons (2015-2020)
  • Table 141. Europe Ambrisentan Drug Sales, by Impairment Type K Tons (2015-2020)
  • Table 142. Europe Ambrisentan Drug Sales, by End-Use K Tons (2015-2020)
  • Table 143. Europe Ambrisentan Drug Sales, by Strength K Tons (2015-2020)
  • Table 144. Germany Ambrisentan Drug Sales, by Impairment Type K Tons (2015-2020)
  • Table 145. Germany Ambrisentan Drug Sales, by End-Use K Tons (2015-2020)
  • Table 146. Germany Ambrisentan Drug Sales, by Strength K Tons (2015-2020)
  • Table 147. France Ambrisentan Drug Sales, by Impairment Type K Tons (2015-2020)
  • Table 148. France Ambrisentan Drug Sales, by End-Use K Tons (2015-2020)
  • Table 149. France Ambrisentan Drug Sales, by Strength K Tons (2015-2020)
  • Table 150. Italy Ambrisentan Drug Sales, by Impairment Type K Tons (2015-2020)
  • Table 151. Italy Ambrisentan Drug Sales, by End-Use K Tons (2015-2020)
  • Table 152. Italy Ambrisentan Drug Sales, by Strength K Tons (2015-2020)
  • Table 153. United Kingdom Ambrisentan Drug Sales, by Impairment Type K Tons (2015-2020)
  • Table 154. United Kingdom Ambrisentan Drug Sales, by End-Use K Tons (2015-2020)
  • Table 155. United Kingdom Ambrisentan Drug Sales, by Strength K Tons (2015-2020)
  • Table 156. Netherlands Ambrisentan Drug Sales, by Impairment Type K Tons (2015-2020)
  • Table 157. Netherlands Ambrisentan Drug Sales, by End-Use K Tons (2015-2020)
  • Table 158. Netherlands Ambrisentan Drug Sales, by Strength K Tons (2015-2020)
  • Table 159. Rest of Europe Ambrisentan Drug Sales, by Impairment Type K Tons (2015-2020)
  • Table 160. Rest of Europe Ambrisentan Drug Sales, by End-Use K Tons (2015-2020)
  • Table 161. Rest of Europe Ambrisentan Drug Sales, by Strength K Tons (2015-2020)
  • Table 162. MEA Ambrisentan Drug Sales, by Country K Tons (2015-2020)
  • Table 163. MEA Ambrisentan Drug Sales, by Impairment Type K Tons (2015-2020)
  • Table 164. MEA Ambrisentan Drug Sales, by End-Use K Tons (2015-2020)
  • Table 165. MEA Ambrisentan Drug Sales, by Strength K Tons (2015-2020)
  • Table 166. Middle East Ambrisentan Drug Sales, by Impairment Type K Tons (2015-2020)
  • Table 167. Middle East Ambrisentan Drug Sales, by End-Use K Tons (2015-2020)
  • Table 168. Middle East Ambrisentan Drug Sales, by Strength K Tons (2015-2020)
  • Table 169. Africa Ambrisentan Drug Sales, by Impairment Type K Tons (2015-2020)
  • Table 170. Africa Ambrisentan Drug Sales, by End-Use K Tons (2015-2020)
  • Table 171. Africa Ambrisentan Drug Sales, by Strength K Tons (2015-2020)
  • Table 172. North America Ambrisentan Drug Sales, by Country K Tons (2015-2020)
  • Table 173. North America Ambrisentan Drug Sales, by Impairment Type K Tons (2015-2020)
  • Table 174. North America Ambrisentan Drug Sales, by End-Use K Tons (2015-2020)
  • Table 175. North America Ambrisentan Drug Sales, by Strength K Tons (2015-2020)
  • Table 176. United States Ambrisentan Drug Sales, by Impairment Type K Tons (2015-2020)
  • Table 177. United States Ambrisentan Drug Sales, by End-Use K Tons (2015-2020)
  • Table 178. United States Ambrisentan Drug Sales, by Strength K Tons (2015-2020)
  • Table 179. Canada Ambrisentan Drug Sales, by Impairment Type K Tons (2015-2020)
  • Table 180. Canada Ambrisentan Drug Sales, by End-Use K Tons (2015-2020)
  • Table 181. Canada Ambrisentan Drug Sales, by Strength K Tons (2015-2020)
  • Table 182. Mexico Ambrisentan Drug Sales, by Impairment Type K Tons (2015-2020)
  • Table 183. Mexico Ambrisentan Drug Sales, by End-Use K Tons (2015-2020)
  • Table 184. Mexico Ambrisentan Drug Sales, by Strength K Tons (2015-2020)
  • Table 185. Company Basic Information, Sales Area and Its Competitors
  • Table 186. Company Basic Information, Sales Area and Its Competitors
  • Table 187. Company Basic Information, Sales Area and Its Competitors
  • Table 188. Company Basic Information, Sales Area and Its Competitors
  • Table 189. Company Basic Information, Sales Area and Its Competitors
  • Table 190. Company Basic Information, Sales Area and Its Competitors
  • Table 191. Company Basic Information, Sales Area and Its Competitors
  • Table 192. Company Basic Information, Sales Area and Its Competitors
  • Table 193. Company Basic Information, Sales Area and Its Competitors
  • Table 194. Company Basic Information, Sales Area and Its Competitors
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Ambrisentan Drug: by Impairment Type(USD Million)
  • Table 197. Ambrisentan Drug Renal Impairment , by Region USD Million (2021-2026)
  • Table 198. Ambrisentan Drug Hepatic Impairment , by Region USD Million (2021-2026)
  • Table 199. Ambrisentan Drug: by End-Use(USD Million)
  • Table 200. Ambrisentan Drug Hospitals , by Region USD Million (2021-2026)
  • Table 201. Ambrisentan Drug Specialty Drug Store , by Region USD Million (2021-2026)
  • Table 202. Ambrisentan Drug: by Strength(USD Million)
  • Table 203. Ambrisentan Drug 5mg , by Region USD Million (2021-2026)
  • Table 204. Ambrisentan Drug 10mg , by Region USD Million (2021-2026)
  • Table 205. South America Ambrisentan Drug, by Country USD Million (2021-2026)
  • Table 206. South America Ambrisentan Drug, by Impairment Type USD Million (2021-2026)
  • Table 207. South America Ambrisentan Drug, by End-Use USD Million (2021-2026)
  • Table 208. South America Ambrisentan Drug, by Strength USD Million (2021-2026)
  • Table 209. Brazil Ambrisentan Drug, by Impairment Type USD Million (2021-2026)
  • Table 210. Brazil Ambrisentan Drug, by End-Use USD Million (2021-2026)
  • Table 211. Brazil Ambrisentan Drug, by Strength USD Million (2021-2026)
  • Table 212. Argentina Ambrisentan Drug, by Impairment Type USD Million (2021-2026)
  • Table 213. Argentina Ambrisentan Drug, by End-Use USD Million (2021-2026)
  • Table 214. Argentina Ambrisentan Drug, by Strength USD Million (2021-2026)
  • Table 215. Rest of South America Ambrisentan Drug, by Impairment Type USD Million (2021-2026)
  • Table 216. Rest of South America Ambrisentan Drug, by End-Use USD Million (2021-2026)
  • Table 217. Rest of South America Ambrisentan Drug, by Strength USD Million (2021-2026)
  • Table 218. Asia Pacific Ambrisentan Drug, by Country USD Million (2021-2026)
  • Table 219. Asia Pacific Ambrisentan Drug, by Impairment Type USD Million (2021-2026)
  • Table 220. Asia Pacific Ambrisentan Drug, by End-Use USD Million (2021-2026)
  • Table 221. Asia Pacific Ambrisentan Drug, by Strength USD Million (2021-2026)
  • Table 222. China Ambrisentan Drug, by Impairment Type USD Million (2021-2026)
  • Table 223. China Ambrisentan Drug, by End-Use USD Million (2021-2026)
  • Table 224. China Ambrisentan Drug, by Strength USD Million (2021-2026)
  • Table 225. Japan Ambrisentan Drug, by Impairment Type USD Million (2021-2026)
  • Table 226. Japan Ambrisentan Drug, by End-Use USD Million (2021-2026)
  • Table 227. Japan Ambrisentan Drug, by Strength USD Million (2021-2026)
  • Table 228. India Ambrisentan Drug, by Impairment Type USD Million (2021-2026)
  • Table 229. India Ambrisentan Drug, by End-Use USD Million (2021-2026)
  • Table 230. India Ambrisentan Drug, by Strength USD Million (2021-2026)
  • Table 231. South Korea Ambrisentan Drug, by Impairment Type USD Million (2021-2026)
  • Table 232. South Korea Ambrisentan Drug, by End-Use USD Million (2021-2026)
  • Table 233. South Korea Ambrisentan Drug, by Strength USD Million (2021-2026)
  • Table 234. Taiwan Ambrisentan Drug, by Impairment Type USD Million (2021-2026)
  • Table 235. Taiwan Ambrisentan Drug, by End-Use USD Million (2021-2026)
  • Table 236. Taiwan Ambrisentan Drug, by Strength USD Million (2021-2026)
  • Table 237. Australia Ambrisentan Drug, by Impairment Type USD Million (2021-2026)
  • Table 238. Australia Ambrisentan Drug, by End-Use USD Million (2021-2026)
  • Table 239. Australia Ambrisentan Drug, by Strength USD Million (2021-2026)
  • Table 240. Rest of Asia-Pacific Ambrisentan Drug, by Impairment Type USD Million (2021-2026)
  • Table 241. Rest of Asia-Pacific Ambrisentan Drug, by End-Use USD Million (2021-2026)
  • Table 242. Rest of Asia-Pacific Ambrisentan Drug, by Strength USD Million (2021-2026)
  • Table 243. Europe Ambrisentan Drug, by Country USD Million (2021-2026)
  • Table 244. Europe Ambrisentan Drug, by Impairment Type USD Million (2021-2026)
  • Table 245. Europe Ambrisentan Drug, by End-Use USD Million (2021-2026)
  • Table 246. Europe Ambrisentan Drug, by Strength USD Million (2021-2026)
  • Table 247. Germany Ambrisentan Drug, by Impairment Type USD Million (2021-2026)
  • Table 248. Germany Ambrisentan Drug, by End-Use USD Million (2021-2026)
  • Table 249. Germany Ambrisentan Drug, by Strength USD Million (2021-2026)
  • Table 250. France Ambrisentan Drug, by Impairment Type USD Million (2021-2026)
  • Table 251. France Ambrisentan Drug, by End-Use USD Million (2021-2026)
  • Table 252. France Ambrisentan Drug, by Strength USD Million (2021-2026)
  • Table 253. Italy Ambrisentan Drug, by Impairment Type USD Million (2021-2026)
  • Table 254. Italy Ambrisentan Drug, by End-Use USD Million (2021-2026)
  • Table 255. Italy Ambrisentan Drug, by Strength USD Million (2021-2026)
  • Table 256. United Kingdom Ambrisentan Drug, by Impairment Type USD Million (2021-2026)
  • Table 257. United Kingdom Ambrisentan Drug, by End-Use USD Million (2021-2026)
  • Table 258. United Kingdom Ambrisentan Drug, by Strength USD Million (2021-2026)
  • Table 259. Netherlands Ambrisentan Drug, by Impairment Type USD Million (2021-2026)
  • Table 260. Netherlands Ambrisentan Drug, by End-Use USD Million (2021-2026)
  • Table 261. Netherlands Ambrisentan Drug, by Strength USD Million (2021-2026)
  • Table 262. Rest of Europe Ambrisentan Drug, by Impairment Type USD Million (2021-2026)
  • Table 263. Rest of Europe Ambrisentan Drug, by End-Use USD Million (2021-2026)
  • Table 264. Rest of Europe Ambrisentan Drug, by Strength USD Million (2021-2026)
  • Table 265. MEA Ambrisentan Drug, by Country USD Million (2021-2026)
  • Table 266. MEA Ambrisentan Drug, by Impairment Type USD Million (2021-2026)
  • Table 267. MEA Ambrisentan Drug, by End-Use USD Million (2021-2026)
  • Table 268. MEA Ambrisentan Drug, by Strength USD Million (2021-2026)
  • Table 269. Middle East Ambrisentan Drug, by Impairment Type USD Million (2021-2026)
  • Table 270. Middle East Ambrisentan Drug, by End-Use USD Million (2021-2026)
  • Table 271. Middle East Ambrisentan Drug, by Strength USD Million (2021-2026)
  • Table 272. Africa Ambrisentan Drug, by Impairment Type USD Million (2021-2026)
  • Table 273. Africa Ambrisentan Drug, by End-Use USD Million (2021-2026)
  • Table 274. Africa Ambrisentan Drug, by Strength USD Million (2021-2026)
  • Table 275. North America Ambrisentan Drug, by Country USD Million (2021-2026)
  • Table 276. North America Ambrisentan Drug, by Impairment Type USD Million (2021-2026)
  • Table 277. North America Ambrisentan Drug, by End-Use USD Million (2021-2026)
  • Table 278. North America Ambrisentan Drug, by Strength USD Million (2021-2026)
  • Table 279. United States Ambrisentan Drug, by Impairment Type USD Million (2021-2026)
  • Table 280. United States Ambrisentan Drug, by End-Use USD Million (2021-2026)
  • Table 281. United States Ambrisentan Drug, by Strength USD Million (2021-2026)
  • Table 282. Canada Ambrisentan Drug, by Impairment Type USD Million (2021-2026)
  • Table 283. Canada Ambrisentan Drug, by End-Use USD Million (2021-2026)
  • Table 284. Canada Ambrisentan Drug, by Strength USD Million (2021-2026)
  • Table 285. Mexico Ambrisentan Drug, by Impairment Type USD Million (2021-2026)
  • Table 286. Mexico Ambrisentan Drug, by End-Use USD Million (2021-2026)
  • Table 287. Mexico Ambrisentan Drug, by Strength USD Million (2021-2026)
  • Table 288. Ambrisentan Drug Sales: by Impairment Type(K Tons)
  • Table 289. Ambrisentan Drug Sales Renal Impairment , by Region K Tons (2021-2026)
  • Table 290. Ambrisentan Drug Sales Hepatic Impairment , by Region K Tons (2021-2026)
  • Table 291. Ambrisentan Drug Sales: by End-Use(K Tons)
  • Table 292. Ambrisentan Drug Sales Hospitals , by Region K Tons (2021-2026)
  • Table 293. Ambrisentan Drug Sales Specialty Drug Store , by Region K Tons (2021-2026)
  • Table 294. Ambrisentan Drug Sales: by Strength(K Tons)
  • Table 295. Ambrisentan Drug Sales 5mg , by Region K Tons (2021-2026)
  • Table 296. Ambrisentan Drug Sales 10mg , by Region K Tons (2021-2026)
  • Table 297. South America Ambrisentan Drug Sales, by Country K Tons (2021-2026)
  • Table 298. South America Ambrisentan Drug Sales, by Impairment Type K Tons (2021-2026)
  • Table 299. South America Ambrisentan Drug Sales, by End-Use K Tons (2021-2026)
  • Table 300. South America Ambrisentan Drug Sales, by Strength K Tons (2021-2026)
  • Table 301. Brazil Ambrisentan Drug Sales, by Impairment Type K Tons (2021-2026)
  • Table 302. Brazil Ambrisentan Drug Sales, by End-Use K Tons (2021-2026)
  • Table 303. Brazil Ambrisentan Drug Sales, by Strength K Tons (2021-2026)
  • Table 304. Argentina Ambrisentan Drug Sales, by Impairment Type K Tons (2021-2026)
  • Table 305. Argentina Ambrisentan Drug Sales, by End-Use K Tons (2021-2026)
  • Table 306. Argentina Ambrisentan Drug Sales, by Strength K Tons (2021-2026)
  • Table 307. Rest of South America Ambrisentan Drug Sales, by Impairment Type K Tons (2021-2026)
  • Table 308. Rest of South America Ambrisentan Drug Sales, by End-Use K Tons (2021-2026)
  • Table 309. Rest of South America Ambrisentan Drug Sales, by Strength K Tons (2021-2026)
  • Table 310. Asia Pacific Ambrisentan Drug Sales, by Country K Tons (2021-2026)
  • Table 311. Asia Pacific Ambrisentan Drug Sales, by Impairment Type K Tons (2021-2026)
  • Table 312. Asia Pacific Ambrisentan Drug Sales, by End-Use K Tons (2021-2026)
  • Table 313. Asia Pacific Ambrisentan Drug Sales, by Strength K Tons (2021-2026)
  • Table 314. China Ambrisentan Drug Sales, by Impairment Type K Tons (2021-2026)
  • Table 315. China Ambrisentan Drug Sales, by End-Use K Tons (2021-2026)
  • Table 316. China Ambrisentan Drug Sales, by Strength K Tons (2021-2026)
  • Table 317. Japan Ambrisentan Drug Sales, by Impairment Type K Tons (2021-2026)
  • Table 318. Japan Ambrisentan Drug Sales, by End-Use K Tons (2021-2026)
  • Table 319. Japan Ambrisentan Drug Sales, by Strength K Tons (2021-2026)
  • Table 320. India Ambrisentan Drug Sales, by Impairment Type K Tons (2021-2026)
  • Table 321. India Ambrisentan Drug Sales, by End-Use K Tons (2021-2026)
  • Table 322. India Ambrisentan Drug Sales, by Strength K Tons (2021-2026)
  • Table 323. South Korea Ambrisentan Drug Sales, by Impairment Type K Tons (2021-2026)
  • Table 324. South Korea Ambrisentan Drug Sales, by End-Use K Tons (2021-2026)
  • Table 325. South Korea Ambrisentan Drug Sales, by Strength K Tons (2021-2026)
  • Table 326. Taiwan Ambrisentan Drug Sales, by Impairment Type K Tons (2021-2026)
  • Table 327. Taiwan Ambrisentan Drug Sales, by End-Use K Tons (2021-2026)
  • Table 328. Taiwan Ambrisentan Drug Sales, by Strength K Tons (2021-2026)
  • Table 329. Australia Ambrisentan Drug Sales, by Impairment Type K Tons (2021-2026)
  • Table 330. Australia Ambrisentan Drug Sales, by End-Use K Tons (2021-2026)
  • Table 331. Australia Ambrisentan Drug Sales, by Strength K Tons (2021-2026)
  • Table 332. Rest of Asia-Pacific Ambrisentan Drug Sales, by Impairment Type K Tons (2021-2026)
  • Table 333. Rest of Asia-Pacific Ambrisentan Drug Sales, by End-Use K Tons (2021-2026)
  • Table 334. Rest of Asia-Pacific Ambrisentan Drug Sales, by Strength K Tons (2021-2026)
  • Table 335. Europe Ambrisentan Drug Sales, by Country K Tons (2021-2026)
  • Table 336. Europe Ambrisentan Drug Sales, by Impairment Type K Tons (2021-2026)
  • Table 337. Europe Ambrisentan Drug Sales, by End-Use K Tons (2021-2026)
  • Table 338. Europe Ambrisentan Drug Sales, by Strength K Tons (2021-2026)
  • Table 339. Germany Ambrisentan Drug Sales, by Impairment Type K Tons (2021-2026)
  • Table 340. Germany Ambrisentan Drug Sales, by End-Use K Tons (2021-2026)
  • Table 341. Germany Ambrisentan Drug Sales, by Strength K Tons (2021-2026)
  • Table 342. France Ambrisentan Drug Sales, by Impairment Type K Tons (2021-2026)
  • Table 343. France Ambrisentan Drug Sales, by End-Use K Tons (2021-2026)
  • Table 344. France Ambrisentan Drug Sales, by Strength K Tons (2021-2026)
  • Table 345. Italy Ambrisentan Drug Sales, by Impairment Type K Tons (2021-2026)
  • Table 346. Italy Ambrisentan Drug Sales, by End-Use K Tons (2021-2026)
  • Table 347. Italy Ambrisentan Drug Sales, by Strength K Tons (2021-2026)
  • Table 348. United Kingdom Ambrisentan Drug Sales, by Impairment Type K Tons (2021-2026)
  • Table 349. United Kingdom Ambrisentan Drug Sales, by End-Use K Tons (2021-2026)
  • Table 350. United Kingdom Ambrisentan Drug Sales, by Strength K Tons (2021-2026)
  • Table 351. Netherlands Ambrisentan Drug Sales, by Impairment Type K Tons (2021-2026)
  • Table 352. Netherlands Ambrisentan Drug Sales, by End-Use K Tons (2021-2026)
  • Table 353. Netherlands Ambrisentan Drug Sales, by Strength K Tons (2021-2026)
  • Table 354. Rest of Europe Ambrisentan Drug Sales, by Impairment Type K Tons (2021-2026)
  • Table 355. Rest of Europe Ambrisentan Drug Sales, by End-Use K Tons (2021-2026)
  • Table 356. Rest of Europe Ambrisentan Drug Sales, by Strength K Tons (2021-2026)
  • Table 357. MEA Ambrisentan Drug Sales, by Country K Tons (2021-2026)
  • Table 358. MEA Ambrisentan Drug Sales, by Impairment Type K Tons (2021-2026)
  • Table 359. MEA Ambrisentan Drug Sales, by End-Use K Tons (2021-2026)
  • Table 360. MEA Ambrisentan Drug Sales, by Strength K Tons (2021-2026)
  • Table 361. Middle East Ambrisentan Drug Sales, by Impairment Type K Tons (2021-2026)
  • Table 362. Middle East Ambrisentan Drug Sales, by End-Use K Tons (2021-2026)
  • Table 363. Middle East Ambrisentan Drug Sales, by Strength K Tons (2021-2026)
  • Table 364. Africa Ambrisentan Drug Sales, by Impairment Type K Tons (2021-2026)
  • Table 365. Africa Ambrisentan Drug Sales, by End-Use K Tons (2021-2026)
  • Table 366. Africa Ambrisentan Drug Sales, by Strength K Tons (2021-2026)
  • Table 367. North America Ambrisentan Drug Sales, by Country K Tons (2021-2026)
  • Table 368. North America Ambrisentan Drug Sales, by Impairment Type K Tons (2021-2026)
  • Table 369. North America Ambrisentan Drug Sales, by End-Use K Tons (2021-2026)
  • Table 370. North America Ambrisentan Drug Sales, by Strength K Tons (2021-2026)
  • Table 371. United States Ambrisentan Drug Sales, by Impairment Type K Tons (2021-2026)
  • Table 372. United States Ambrisentan Drug Sales, by End-Use K Tons (2021-2026)
  • Table 373. United States Ambrisentan Drug Sales, by Strength K Tons (2021-2026)
  • Table 374. Canada Ambrisentan Drug Sales, by Impairment Type K Tons (2021-2026)
  • Table 375. Canada Ambrisentan Drug Sales, by End-Use K Tons (2021-2026)
  • Table 376. Canada Ambrisentan Drug Sales, by Strength K Tons (2021-2026)
  • Table 377. Mexico Ambrisentan Drug Sales, by Impairment Type K Tons (2021-2026)
  • Table 378. Mexico Ambrisentan Drug Sales, by End-Use K Tons (2021-2026)
  • Table 379. Mexico Ambrisentan Drug Sales, by Strength K Tons (2021-2026)
  • Table 380. Research Programs/Design for This Report
  • Table 381. Key Data Information from Secondary Sources
  • Table 382. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Ambrisentan Drug: by Impairment Type USD Million (2015-2020)
  • Figure 5. Global Ambrisentan Drug: by End-Use USD Million (2015-2020)
  • Figure 6. Global Ambrisentan Drug: by Strength USD Million (2015-2020)
  • Figure 7. South America Ambrisentan Drug Share (%), by Country
  • Figure 8. Asia Pacific Ambrisentan Drug Share (%), by Country
  • Figure 9. Europe Ambrisentan Drug Share (%), by Country
  • Figure 10. MEA Ambrisentan Drug Share (%), by Country
  • Figure 11. North America Ambrisentan Drug Share (%), by Country
  • Figure 12. Global Ambrisentan Drug: by Impairment Type K Tons (2015-2020)
  • Figure 13. Global Ambrisentan Drug: by End-Use K Tons (2015-2020)
  • Figure 14. Global Ambrisentan Drug: by Strength K Tons (2015-2020)
  • Figure 15. South America Ambrisentan Drug Share (%), by Country
  • Figure 16. Asia Pacific Ambrisentan Drug Share (%), by Country
  • Figure 17. Europe Ambrisentan Drug Share (%), by Country
  • Figure 18. MEA Ambrisentan Drug Share (%), by Country
  • Figure 19. North America Ambrisentan Drug Share (%), by Country
  • Figure 20. Global Ambrisentan Drug share by Players 2020 (%)
  • Figure 21. Global Ambrisentan Drug share by Players (Top 3) 2020(%)
  • Figure 22. Global Ambrisentan Drug share by Players (Top 5) 2020(%)
  • Figure 23. BCG Matrix for key Companies
  • Figure 24. Mylan S.A.S. (United States) Revenue, Net Income and Gross profit
  • Figure 25. Mylan S.A.S. (United States) Revenue: by Geography 2020
  • Figure 26. Gilead Sciences, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Gilead Sciences, Inc. (United States) Revenue: by Geography 2020
  • Figure 28. Glaxo Smith Kline Limited (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 29. Glaxo Smith Kline Limited (United Kingdom) Revenue: by Geography 2020
  • Figure 30. Cipla Inc. (India) Revenue, Net Income and Gross profit
  • Figure 31. Cipla Inc. (India) Revenue: by Geography 2020
  • Figure 32. Par Pharmaceutical, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. Par Pharmaceutical, Inc. (United States) Revenue: by Geography 2020
  • Figure 34. Sigmapharm Laboratories, LLC (United States) Revenue, Net Income and Gross profit
  • Figure 35. Sigmapharm Laboratories, LLC (United States) Revenue: by Geography 2020
  • Figure 36. Sun Pharmaceutical Industries, Inc. (India) Revenue, Net Income and Gross profit
  • Figure 37. Sun Pharmaceutical Industries, Inc. (India) Revenue: by Geography 2020
  • Figure 38. Cadila Healthcare Limited (India) Revenue, Net Income and Gross profit
  • Figure 39. Cadila Healthcare Limited (India) Revenue: by Geography 2020
  • Figure 40. Exelan Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 41. Exelan Pharmaceuticals, Inc. (United States) Revenue: by Geography 2020
  • Figure 42. Actavis Pharma, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 43. Actavis Pharma, Inc. (United States) Revenue: by Geography 2020
  • Figure 44. Hansoh Pharma (China) Revenue, Net Income and Gross profit
  • Figure 45. Hansoh Pharma (China) Revenue: by Geography 2020
  • Figure 46. Global Ambrisentan Drug: by Impairment Type USD Million (2021-2026)
  • Figure 47. Global Ambrisentan Drug: by End-Use USD Million (2021-2026)
  • Figure 48. Global Ambrisentan Drug: by Strength USD Million (2021-2026)
  • Figure 49. South America Ambrisentan Drug Share (%), by Country
  • Figure 50. Asia Pacific Ambrisentan Drug Share (%), by Country
  • Figure 51. Europe Ambrisentan Drug Share (%), by Country
  • Figure 52. MEA Ambrisentan Drug Share (%), by Country
  • Figure 53. North America Ambrisentan Drug Share (%), by Country
  • Figure 54. Global Ambrisentan Drug: by Impairment Type K Tons (2021-2026)
  • Figure 55. Global Ambrisentan Drug: by End-Use K Tons (2021-2026)
  • Figure 56. Global Ambrisentan Drug: by Strength K Tons (2021-2026)
  • Figure 57. South America Ambrisentan Drug Share (%), by Country
  • Figure 58. Asia Pacific Ambrisentan Drug Share (%), by Country
  • Figure 59. Europe Ambrisentan Drug Share (%), by Country
  • Figure 60. MEA Ambrisentan Drug Share (%), by Country
  • Figure 61. North America Ambrisentan Drug Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Mylan S.A.S. (United States)
  • Gilead Sciences, Inc. (United States)
  • Glaxo Smith Kline Limited (United Kingdom)
  • Cipla Inc. (India)
  • Par Pharmaceutical, Inc. (United States)
  • Sigmapharm Laboratories, LLC (United States)
  • Sun Pharmaceutical Industries, Inc. (India)
  • Cadila Healthcare Limited (India)
  • Exelan Pharmaceuticals, Inc. (United States)
  • Actavis Pharma, Inc. (United States)
  • Hansoh Pharma (China)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation